$RVVTF this news release feels unusually restrained given the significance of the DRDC results.
Remember, the March patent news triggered an ~88% move, yet this potentially much more important DRDC efficacy update has barely moved the stock.
DRDC also controls what Revive can publicly disclose, so there may be considerably more context around the program that simply cannot be discussed yet.
And if the Canadian government is ultimately looking at procurement, seems there's an obvious incentive for negotiations to happen before the market fully reprices the company. IMO the best is yet to come and this smells purposefully coordinate…
$RVVTF
So is it possible that we hear some more news regarding the nerve-agent find before Q4 2026?? But on any additional studies regarding potential effects on brain injury, 'oxidative stress (Molecular Hydrogen - 2025 DiagnaMed Holdings Corp acquisition ?) , response to standard treatment and respiratory function which starts in Q4 2026. So is MF now allowed to pursue partnership, revenue opportunities for the Nerve Agent research study while we wait for the additional studies scheduled for Q4 2026?
$RVVTF hopefully next PR says something along the lines of, DRDC/Canadian government is proceeding with confirmatory studies based on the positive results
$RVVTF
I want to come back yet again to PR that Michael Frank sent out on 4/1/2025. This was regarding accuiring DiagnaMed's Molecular Hydrogen Program. Why it might possibly be more relevant than ever now is due to the verbiage in the 8/12/2026 DRDC positive Press Release which features the phrase "DRDC will continue its research on bucillamine through additional confirmatory studies scheduled to begin in Q4-2026. Additional research will evaluate its potential effects on brain injury, oxidative stress". https://revivethera.com/2025/04/revive-therapeutics-announces-acquisition-of-molecular-hydrogen-program/
The same phrase 'Oxidative stress' appears in an article on the Universal Neurological Care website titled 'How does Molecular Hydrogen Work? It's Benefits and Functions'. I wonder if RVVTF's Molecular Hydrogen accuiqustion might play a role in the DRDC research is performing currently in addition to RVVTF to this PR sent out 4/10/2025 regarding working an US Cancer Research Center??? https://universalneurocare.com/how-does-molecular-hydrogen-work/
$RVVTF
No Pump - Did MF possibly hint at a Nato partnership???
The phrase 'strategic organizations.strategic organizations' appears twice in the 8/12/2026 PR. Is it just nothing burger verbiage or a major Easter egg?? What are the names of strategic organizations that are out there could he possibly be referring to??
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-reports-positive-results-from-drdc-bucillamine-ne-1206464
$RVVTF Least at this point MFrank should be able to complete the balance of $1m funding he was trying to raise. After that - Revive should be able to focus on a few specific projects to further the progess of Buci. Still think 4th quarter will be the breakout mark for RVVTF. Agree 100% MFrank should find a "partner" as past experiences don't install confidence... Think with this announcement we'll start seeing a small handful of positive press releases & other media coverage that'll bring attention to & hopefully new investors for RVVTF... Today was a "baseline of good things to come" -- Patience Pays...
$RVVTF Armed with these results that show that bucillamine prevents brain injury from chemical weapons, MF should aggressively seek non dilutive financing or a partnership with a multi billion dollar agri chemical or big pharma corporation for its potential use for civilian insecticide poisoning since their identical.
$RVVTF I guess this is related to RVV to further evaluate for TBI.
https://redcliff.ca/planned-large-scale-blast-at-cfb-suffield-between-august-12th-and-13th/
$RVVTF So positive results and Canadian government continuing to evaluate efficacy for not only nerve agent but other medical issues, so only thing I can think of for low excitement is that OTC’s tend to want news of overnight success, not that success is expected in 2027. “… positive results from a research study conducted by Defence Research and Development Canada - Suffield Research Centre (DRDC)” … “DRDC will continue its research on bucillamine through additional confirmatory studies scheduled to begin in Q4-2026. Additional research will evaluate its potential effects on brain injury, oxidative stress, response to standard treatment and respiratory function.”
https://revivethera.com/2026/08/revive-therapeutics-reports-positive-results-from-drdc-bucillamine-nerve-agent-research-study/
